"10.1371_journal.pone.0118830","plos one","2015-03-04T00:00:00Z","Lars BÃ¶rnsen; Jeppe Romme Christensen; Rikke Ratzer; Chris Hedegaard; Helle B SÃ¸ndergaard; Martin Krakauer; Dan Hesse; Claus H Nielsen; Per S Sorensen; Finn Sellebjerg","Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Institute for Inflammation Research, Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark","Conceived and designed the experiments: LB JRC CH HBS MK DH CHN PSS FS. Performed the experiments: LB JRC RR CH HBS MK. Analyzed the data: LB JRC HBS FS. Contributed reagents/materials/analysis tools: CHN PSS FS. Wrote the paper: LB FS.","The authors have the following interests. Lars BÃ¶rnsen has had travel expenses reimbursed by Novartis for congress participation. Jeppe Romme Christensen has received speaker honoraria from Genzyme, received consultant honoraria from Biogen Idec and Royalty Pharma and has had travel expenses reimbursed by Merck Serono. Rikke Ratzer has had travel expenses reimbursed by Merck Serono, TEVA, Biogen Idec and Sanofi Aventis. Dan Hesse has received funding for travel from Biogen Idec, Merck-Serono, and Sanofi-Aventis; and received speaker honoraria from Sanofi-Aventis. Claus H. Nielsen has received speaker honoraria from Roche, Bristol-Myers Squibb and Schering-Plough. Per Soelberg Sorensen has served on scientific advisory boards for and received funding of travel for these activities from Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan; has served as Editor-in-Chief of the European Journal of Neurology, and as an editorial board member for Therapeutic Advances in Neurological Disorders and Multiple Sclerosis; receives speaker honoraria from Biogen Idec, Merck Serono, TEVA, Bayer Schering, Sanofiaventis, and Novartis; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, and Genzyme. Finn Sellebjerg has served on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva; has received funding for travel from Sanofi-Aventis and Teva; has served as a consultant for Novo Nordisk; has received speaker honoraria from Bayer-Schering, Biogen Idec, Merck-Serono, Sanofi-Aventis, Schering- Ploug; and has received research support from Biogen Idec and Sanofi-Aventis. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","03","Lars BÃ¶rnsen","LBÃ",10,TRUE,9,6,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
